

Company Overview

CollPlant is a regenerative and aesthetic medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing.

Our revolutionary plant-based technology is the only commercially viable technology for mass production of recombinant human Type I collagen (rhCollagen), which is identical to the collagen produced by the human body. This makes our rhCollagen the ideal building block for regenerative medicine. Leveraging on the unique properties of rhCollagen and biomaterial know-how, we are developing a pipeline of products aimed at 3D bioprinting of tissues and organs and medical aesthetics.

Our mission at CollPlant is to deliver ground-breaking products for regenerative medicine that offer the optimal treatment options to patients.

CollPlant Announces Publication Highlighting its rhCollagen-based Photocurable Dermal Filler in the Plastic and Reconstructive Surgery Journal

Dec 2 2021, 7:00 AM EST

CollPlant Biotechnologies Provides Business Updates and Third Quarter 2021 Financial Results

Nov 18 2021, 7:00 AM EST

CollPlant Announces Commercial Launch of BioInk Platform with Collink.3D™ for Use in 3D Bioprinting of Human Tissues, Scaffolds and Organs

Nov 15 2021, 7:00 AM EST

Stock Overview

Symbol	CLGN
Exchange	Nasdaq
Market Cap	173.01m
Last Price	\$17.45
52-Week Range	\$15.67 - \$23.49

12/02/2021 04:00 PM EST

Investor Relations

Eran Rotem
Deputy CEO & CFO
T: +972 (73) 2325612
F: +972 (73) 2325602
eran@collplant.com

Management Team

Yehiel Tal

Chief Executive Officer

Prof. Oded Shoseyov

Founder, Chief Scientist

Eran Rotem, CPA

Deputy CEO and Chief Financial Officer

Dr. Nadav Orr

Vice President, Research and Development

Dr. Ilana Belzer

Chief Operating Officer

Dr. Philippe Bensimon

Vice President, Regulatory Affairs and Quality Assurance

Hadas Dreihor Horowitz

Vice President of Human Resources

CollPlant Biotechnologies Ltd.

4 Oppenheimer St.,
P.O.B 4132
Rehovot 7670104,
Israel

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.